CHOP chemotherapy of intermediate and high-grade non-Hodgkin's lymphoma

• Published in: Acta oncologica Vol. 33; no. 8; p. 935
• Main Authors: Llanos, M, Tabernero, J, Brunet, J, Amenedo, M, Pallares, C, de Andres, L, Lopez, J J
• Format: Journal Article
• Language: English
• Published: England 1994
• Subjects: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cyclophosphamide - administration & dosage; Doxorubicin - administration & dosage; Female; Humans; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - pathology; Male; Middle Aged; Prednisone - administration & dosage; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine - administration & dosage
• ISSN: 0284-186X; 1651-226X
• DOI: 10.3109/02841869409098460

The results of CHOP treatment in 63 patients with intermediate and high-grade non-Hodgkin's lymphoma (Working Formulation D to I), Ann Arbor stage I to IV were analyzed. The response rate was 87%, 71% complete remission and 16% partial remission with a mean duration of 22 months. The 5-year actuarial survival was 61% (95% confidence interval, 51-70%). The treatment was well tolerated and no deaths due to acute toxicity were observed. Poor prognostic factors in univariate analysis were: high-grade histology, stages III and IV, B symptoms, > or = 4 affected lymph node regions, Karnofsky index < or = 70, erythrocyte sedimentation rate (ESR) > 60 mm, haemoglobin < 100 g/l and elevated lactic dehydrogenase (LDH). Poor prognostic factors in multivariate analysis were: high-grade histology, stages III and IV, haemoglobin < 100 g/l and elevated LDH. In summary, good results were obtained with CHOP chemotherapy, without severe toxicity.